Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT00721669 (Clinical Trial / IMGN388)

Study Title
A Phase I Dose-Escalation Study of IMGN388 in Patients With Solid Tumors (NCT00721669)

Trial Description
Primary objective is to evaluate the safety and PK of IMGN388. This trial is sponsored by ImmunoGen, Inc. [1]

Study Data

  • Condition: Solid Tumor
  • Interventions:
    • Drugs used in this trial
      • IMGN388
  • Phase: I
  • Enrollment: 60
  • Start: June 2008
  • Completion: December 2012
  • Last verified: September 2013

Study Schematic 

(Coming soon)


Last Editorial review: September 29, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar